Gemtuzumab in Treating Patients With Myelodysplastic Syndrome

Summary

RATIONALE: Monoclonal antibodies such as gemtuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Randomized phase II trial to study the effectiveness of gemtuzumab in treating patients who have myelodysplastic syndrome.

Timeline

Start

2001-09

Primary completion

—

Completion

—

Drugs

Indications